Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 20.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PREX ISIN: US00901B1052 Ticker-Symbol: HXB2 
Tradegate
18.10.19
16:38 Uhr
0,510 Euro
-0,003
-0,60 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AIM IMMUNOTECH INC Chart 1 Jahr
5-Tage-Chart
AIM IMMUNOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,503
0,517
18.10.

Aktuelle News zur AIM IMMUNOTECH Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
AIM IMMUNOTECH Aktien ab 5,00 US-Dollar handeln - Ohne versteckte Kosten!
DoAIM ImmunoTech Inc. - 8-K, Current Report-
08.10.AIM ImmunoTech says raised approximately $10 million from public markets over past few months to support lead drug cancer candidate4
07.10.AIM ImmunoTech up 12% on trial update, improved cash position2
07.10.AIM ImmunoTech Inc. - 8-K, Current Report1
07.10.AIM ImmunoTech Inc: AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified438Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer Trials OCALA...
► Artikel lesen
25.09.AIM Immunotech down 43% after pricing equity offering14
25.09.AIM ImmunoTech Inc: AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering246OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE American:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
► Artikel lesen
24.09.AIM ImmunoTech Inc. - S-1/A, General form for registration of securities9
24.09.Savara and AIM ImmunoTech among healthcare gainers; Clovis Oncology and Neogen among losers9
24.09.AIM Immunotech up 55% premarket after DoD grant for Ampligen in BMBC6
24.09.AIM ImmunoTech Inc. - 8-K, Current Report3
24.09.AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center221New Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn 'Breakthrough Award' OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma...
► Artikel lesen
24.09.AIM ImmunoTech Inc: AIM ImmunoTech's Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome167Important Milestone to Commercial Launch in Argentina Achieved OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and...
► Artikel lesen
19.09.Mid-Afternoon Market Update: Dow Turns Red; AIM ImmunoTech Shares Spike Higher5
19.09.AIM ImmunoTech leads healthcare gainers; Zynerba Pharmaceuticals leads the losers6
19.09.NA Proactive news snapshot: CB2 Insights, Avalon GloboCare, AIM ImmunoTech, Capstone Turbine …2
19.09.AIM ImmunoTech Shares Spike Up 90% After $6.42M 'Breakthrough Award'8
19.09.AIM Immunotech up 105% premarket after DOD grant for cancer study6
19.09.AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer412New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns 'Breakthrough Award' OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma...
► Artikel lesen
16.09.AIM ImmunoTech Inc. - 8-K, Current Report1
Seite:  Weiter >>
77 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,1